23 Feb Sernova
Philip Toleikis, Ph.D., CEO and President
April 13 | 3:45pm | BioCentriq Ballroom
London Ontario, Canada
(NASDAQ: SVA)
Sernova is a clinical-stage biotechnology company developing therapeutic cell technologies with a goal to deliver a ‘functional cure’ for chronic diseases, including insulin-dependent diabetes, thyroid disease, and hemophilia A. Sernova has developed the Cell Pouch System™, an implantable, scalable, and retrievable medical device which forms a natural environment for long-term survival and function of immune-protected therapeutic cells. In Sernova’s T1D clinical program, the first three patients to complete the trial protocol have achieved insulin independence. A second patient cohort has now been initiated with interim results expected in H2, 2023. In 2022, Sernova and Evotec (NASDAQ: EVO) entered into a partnership to develop an off-the-shelf iPSC-based islet replacement therapy for potentially millions of patients with diabetes. Sernova has licensed a technology from the University of Miami to cloak cells, potentially eliminating the need for immunosuppressives to protect against immune system attack.
